The Clinically Isolated Syndrome (CIS) is a first clinical episode of central nervous system demyelination with MRI findings suggestive of multiple sclerosis but full criteria for dissemination in space and time used for definite MS diagnosis have not been fulfilled yet. CIS is suspected based on acute or subacute neurologic symptoms that last at least 24 hours but fewer than six months without alternative diagnosis. The main symptoms involve sensory, motor or visual impairment which may include weakness or tingling sensation in the limbs, vision problems, sensory disturbances, eye movement abnormalities, unsteady gait etc.
The clinically isolated syndrome (CIS) market is estimated to be valued at USD 16.03 Bn in 2024 and is expected to reach USD 25.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.
Key players operating in the Clinically Isolated Syndrome market are Teva Pharmaceuticals, Biogen, Merck KGaA, Sanofi, Novartis, Bayer and others.
The Clinically Isolated Syndrome (CIS) Market is witnessing high growth owing to the rising prevalence of multiple sclerosis globally and increase in awareness regarding early diagnosis and treatment. According to the National Multiple Sclerosis Society, nearly 1 million people are affected by MS worldwide.
Technological advancements in diagnostic tools such as magnetic resonance imaging (MRI) for detection of lesions in the brain and spinal cord have improved the ability to accurately diagnose CIS and differentiate it from other conditions with similar symptoms. New disease modifying therapies entered in the market in recent years providing more treatment options for patients.
Market Trends
Increasing R&D investments by key pharmaceutical companies to develop novel oral therapies for CIS and multiple sclerosis. Major players are focusing on developing therapies with improved efficacy and safety profile along with better patient compliance.
Growing focus on development of innovative diagnostic technologies such as fluid biomarkers, optical coherence tomography and axonal loss measures on MRI for early and accurate diagnosis of CIS progression to clinically definite multiple sclerosis. This will help clinicians to start appropriate treatment in a timely manner.
Market Opportunities
Emerging markets in Asia Pacific region expected to drive future growth owing to rising healthcare expenditure ability and awareness about neurological disorders. Combination therapies emerging as a potential opportunity to achieve high treatment effectiveness for CIS patients. Combining drugs with different mechanisms of action may provide additive or synergistic benefits over monotherapies.
Impact of COVID-19 on Clinically Isolated Syndrome Market Growth
The COVID-19 pandemic has significantly impacted the growth of clinically isolated syndrome market. During the pre-pandemic period, the market was growing at a steady pace owing to increasing research initiatives and diagnosis rates. However, the outbreak of coronavirus infection led to sudden decline in new patient registrations and diagnosis rates globally. Various factors such as lockdowns, movement restrictions, and diversion of healthcare resources towards COVID-19 management affected the market negatively.
The hospitals and clinics had to temporarily halt the elective and non-emergency procedures to free up resources for COVID care. This led to postponement of various CIS diagnostic tests and delayed treatment initiation for new patients. Even the ongoing clinical trials were put on hold or delayed due to operational hurdles caused by the pandemic.
The key players are focusing on telemedicine and digital health tools to continue patient engagements and minimize treatment gaps during such crisis. In the post-pandemic future, manufacturers are likely to focus on capacity expansion, strategic partnerships, and product innovations to boost market recovery. Governments are also supporting initiatives for improved access to CIS diagnosis and management services.
Geographical Regions with Highest Clinically Isolated Syndrome Market Value
North America dominated the global clinically isolated syndrome market and accounted for over 35% of the total market value in the pre-COVID year of 2019. Factors such as robust healthcare infrastructure, rising per capita healthcare spending, and presence of major industry players drove the North America market. The United States represented the largest share majorly due to new cases, increasing awareness, favorable insurance, and accessibility of advanced treatments.
Europe held the second position with over 30% value share in 2019.
Fastest Growing Region for Clinically Isolated Syndrome Market
Asia Pacific region is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, growing medical tourism, and rising healthcare expenditure across emerging countries. In particular, China and India are likely to be the hotspots driving the Asia Pacific clinically isolated syndrome market due to increasing diagnosis rates, large patient pools, and availability of low-cost treatments.
Favorable government policies supporting healthcare modernization along with initiatives raising CIS awareness will further support Asia Pacific to outpace other global regions in terms of market growth rates. Additionally, strategic entry of key players and partnership with local players will aid technology transfer and service expansions to tap Asia Pacific's high potential.
Get more insights on: Clinically Isolated Syndrome (CIS) Market
Get this Report in Japanese Language: 臨床的孤立症候群（CIS）市場
Get this Report in Korean Language: 임상적으로 고립된 증후군(CIS) 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)